HBR IdeaCast CEO Series: 23andMe’s Anne Wojcicki on Scientific Breakthroughs and Public Trust
May 20, 2021
Anne Wojcicki, CEO of 23andMe, is a visionary in DNA testing and personalized medicine. She discusses the challenges of leading a groundbreaking company at the intersection of science and consumer trust. Wojcicki highlights the importance of transparency in data privacy, enabling informed choices. She also shares insights on the role of genetic research during the COVID-19 pandemic, revealing intriguing findings about blood type O. Lastly, she reflects on the competitive landscape of genetic testing and the potential of direct-to-consumer healthcare in improving personal health decisions.
AI Snips
Chapters
Transcript
Episode notes
Healthcare System Inertia
- Wojcicki believes healthcare systems struggle to change from within due to entrenched interests.
- She designed 23andMe to empower consumers outside this system.
Embracing Controversy
- Inspired by HIV activists, 23andMe anticipated controversy.
- Wojcicki aimed to put consumer empowerment at the heart of healthcare change.
Regulatory Shifts
- Initially, 23andMe wasn't classified as a medical device, but this changed with the Obama administration.
- This highlights the dynamic nature of regulations, especially in emerging industries.